ADM and Sepsis: In the second approach, a humanized ADM-binding antibody (Adrecizumab, HAM8101) was shown to increase plasma ADM levels and reduce systemic inflammation and endotoxin-induced flu-like symptoms in sepsis models [38,150,151,152].